Tanespimycin as Antitumor Therapy
- 1 February 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1), 17-22
- https://doi.org/10.3816/clml.2011.n.002
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- Heat Shock Protein 90 as a Drug Target: Some Like It HotClinical Cancer Research, 2008
- Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic MelanomaClinical Cancer Research, 2008
- Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cellsBlood, 2007
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple MyelomaClinical Cancer Research, 2006
- Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Proceedings of the National Academy of Sciences of the United States of America, 2006
- STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survivalBlood, 2006
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Blood, 2005
- Clinical and biological significance of HSP89 alpha in human breast cancerInternational Journal of Cancer, 1992